{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:19:30Z","timestamp":1789507170672,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      As a master immune system regulator, transforming growth factor\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 (TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1) is closely linked to the complicated pathophysiology and development of systemic sclerosis (SSc), a multisystem fibrotic disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We aim to evaluate the transcriptional levels of TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 mRNA in PBMCs, assess the TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 serum levels of SSc patients, and compare them with those of healthy subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PBMCs were isolated from whole blood of 50 SSc patients and in 30 healthy controls. After total RNA was extracted from isolated PBMCs, complementary DNA (cDNA) synthesis was performed. Afterward, the expression of TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 mRNA was assessed using quantitative real-time PCR using the SYBR Green, GAPDH, and TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 specific primers. The serum levels of TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 were determined using a commercially available ELISA kit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was a significant upregulation of TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 relative expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), when SSc patients were compared to the control group. The diffuse subgroup was more common in patients with elevated TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 mRNA expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). However, an insignificant difference was observed between the disease subsets of SSc. Serum TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 levels were upregulated in SSc patients (78.35\u2009\u00b1\u200923.16) compared to healthy subjects (61.06\u2009\u00b1\u200915.90), and were considerably higher in SSc patients with ILD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and positive anti-topo-Isomerase antibody (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In patients with SSc, elevated levels of TGF-\n                      <jats:italic>\u03b2<\/jats:italic>\n                      1 in serum and their correlation with clinical symptoms imply that this cytokine may serve as a marker for fibrotic and vascular involvement in SSc.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-024-00433-4","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T07:53:07Z","timestamp":1734940387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the role of active TGF-\u03b21 as inflammatory biomarker in Kashmiri (North-Indian) patients with systemic sclerosis: a case-control study"],"prefix":"10.1186","volume":"64","author":[{"given":"Sakeena","family":"Ayub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabasum","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohi","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaq A.","family":"Dangroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar A.","family":"Bindroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz","family":"Gull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamya Ahmad","family":"Al-Keridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-9303","authenticated-orcid":false,"given":"Zafar Amin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"433_CR1","doi-asserted-by":"crossref","unstructured":"Steen VD, Medsger TA. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am. 1990:1\u201310.","DOI":"10.1016\/S0889-857X(21)01037-1"},{"key":"433_CR2","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013:2737\u201347."},{"key":"433_CR3","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988:202\u20135."},{"key":"433_CR4","unstructured":"S\u00e1nchez-Cano D et al. Interstitial lung disease in systemic sclerosis: Data from the Spanish scleroderma study group. Rheumatol Int. 2018:363\u201374."},{"key":"433_CR5","doi-asserted-by":"crossref","unstructured":"Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 2015:237\u201348.","DOI":"10.1016\/j.rdc.2014.12.005"},{"key":"433_CR6","doi-asserted-by":"crossref","unstructured":"Solomon JJ et al. Scleroderma lung disease. Eur Respir Rev 2013:6\u201319.","DOI":"10.1183\/09059180.00005512"},{"key":"433_CR7","doi-asserted-by":"crossref","unstructured":"Steele R, Hudson M, Lo E, Baron M, Canadian Scleroderma Research Group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res. 2012:519\u201324.","DOI":"10.1002\/acr.21583"},{"key":"433_CR8","doi-asserted-by":"crossref","unstructured":"Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010:863\u201378.","DOI":"10.2217\/imt.10.69"},{"key":"433_CR9","doi-asserted-by":"crossref","unstructured":"Volkmann ER, Varga J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol. 2019;208\u201324.","DOI":"10.1038\/s41584-019-0184-z"},{"key":"433_CR10","unstructured":"Worrell JC, O\u2019Reilly S. Bi-directional communication: Conversations between fibroblasts and immune cells in systemic scle rosis. J Autoimmun. 2020:102526."},{"key":"433_CR11","unstructured":"Bonhomme O et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: Review of the literature. Rheumatology. 2019:67\u20139."},{"key":"433_CR12","doi-asserted-by":"crossref","unstructured":"Guiot J, Moermans C, Henket M, Corhay J-L, Louis R. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017:273\u201380.","DOI":"10.1007\/s00408-017-9993-5"},{"key":"433_CR13","doi-asserted-by":"crossref","unstructured":"Guiot J et al. Exosomal miRNAs in lung diseases: From biologic function to therapeutic targets. J Clin Med. 2019:1345.","DOI":"10.3390\/jcm8091345"},{"key":"433_CR14","doi-asserted-by":"crossref","unstructured":"Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci Sch Ed. 2009:226\u201335.","DOI":"10.2741\/s22"},{"key":"433_CR15","doi-asserted-by":"crossref","unstructured":"Liu J, Chou CL, Wu RY, Pagano JS, Derynck R, Budi EH. Specificity, versatility, and control of TGF-\u03b2 family signaling. Sci Signal. 2019:12\u2013570.","DOI":"10.1126\/scisignal.aav5183"},{"key":"433_CR16","doi-asserted-by":"crossref","unstructured":"Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007:557\u201367.","DOI":"10.1172\/JCI31139"},{"key":"433_CR17","doi-asserted-by":"crossref","unstructured":"Prud\u2019homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis, and immunologic disease, and therapeutic considerations. Lab Investig J Tech Methods Pathol. 2007:1077\u201391.","DOI":"10.1038\/labinvest.3700669"},{"key":"433_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2105-7-85","volume":"7","author":"JS Yuan","year":"2006","unstructured":"Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-time PCR data. BMC Bioinforma. 2006;7:85.","journal-title":"BMC Bioinforma"},{"key":"433_CR19","doi-asserted-by":"crossref","unstructured":"Lafyatis R. Transforming growth factor \u03b2--at the center of systemic sclerosis. Nat Rev Rheumatol 2014:706\u201319.","DOI":"10.1038\/nrrheum.2014.137"},{"key":"433_CR20","doi-asserted-by":"crossref","unstructured":"Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010:822\u20137.","DOI":"10.1136\/ard.2009.111906"},{"key":"433_CR21","doi-asserted-by":"crossref","unstructured":"Assassi S, Arnett FC, Reveille JD, Gourh P, Mayes MD. Clinical, immunologic, and genetic features of familial systemic sclerosis. Arthritis Rheum. 2007:2031\u20137.","DOI":"10.1002\/art.22647"},{"key":"433_CR22","doi-asserted-by":"crossref","unstructured":"Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MI, Brenchley PE. Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis. 1994:763\u20137.","DOI":"10.1136\/ard.53.11.763"},{"key":"433_CR23","doi-asserted-by":"crossref","unstructured":"Vettori S, Cuomo G, Iudici M, D\u2019Abrosca V, Giacco V, Barra G et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol. 2014;663\u20138.","DOI":"10.1007\/s10875-014-0037-0"},{"key":"433_CR24","unstructured":"Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol. 2006:275\u201384."},{"key":"433_CR25","doi-asserted-by":"crossref","unstructured":"Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MIV, Brenchley PEC. Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis. 1994:763\u20137.","DOI":"10.1136\/ard.53.11.763"},{"key":"433_CR26","unstructured":"Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevations with spontaneous regression of skin sclerosis. J Rheumatol. 2006:275\u201384."},{"key":"433_CR27","doi-asserted-by":"crossref","unstructured":"Lomeli-Nieto JA, Monoz-Vallle JF, Zarza JEN, Harnadez CJB, Arellano SG, Navarro AA et al. TGFB1 mRNA expression and frequency of the +\u2009869T\u2009>\u2009C and +\u2009915G\u2009>\u2009C genetic variants: impact on risk for systemic sclerosis. Clin Experimental Med. 2023:1349\u201357.","DOI":"10.1007\/s10238-022-00966-2"},{"key":"433_CR28","doi-asserted-by":"crossref","unstructured":"Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatol Oxf Engl. 2005:1518\u201324.","DOI":"10.1093\/rheumatology\/kei088"},{"key":"433_CR29","doi-asserted-by":"crossref","unstructured":"Yong SJ, Adlakha A, Limper AH. Circulating transforming growth factor-beta (1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest. 2001:68\u201370.","DOI":"10.1378\/chest.120.1_suppl.S68"},{"key":"433_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6064830","author":"TA Dantas","year":"2016","unstructured":"Dantas TA, Concalves SA, de Almeida RA, Pereira CM. Vilar, R]eassessing the Role of the Active TGF-\u03b21 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations. Dis Markers. 2016. https:\/\/doi.org\/10.1155\/2016\/6064830.","journal-title":"Dis Markers"},{"key":"433_CR31","doi-asserted-by":"crossref","unstructured":"Molina-Molina M, Lario S, Luburich P, Ram\u00edrez J, Carri\u00f3n MT, Xaubet A. Quantifying plasma levels of transforming growth factor \u03b21 in idiopathic pulmonary fibrosis. Arch Bronconeumol. 2006:380\u20133.","DOI":"10.1016\/S1579-2129(06)60550-8"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00433-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:33:49Z","timestamp":1782815629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-024-00433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1186\/s42358-024-00433-4","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Ethics Committee (IEC-SKIMS) approved the study vide protocol number #RP77\/2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"After giving their informed consent and having the right to withdraw at any moment, participants willingly decided to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patients who participated in this study gave written informed consent for participation and publication of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}